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'Map and zap' - electrode catheter techniques for
treattnent of supraventricular tachycardias
R. N. SCOTT MILLAR, D. A. MILNE, I. w. P. OBEL
C ardiac electrophysiologists around the worldhave become increasingly interested in the use ofelectrode catheters to ablate critical areas
involved in the genesis and transmission of supra-
ventricular tacbycardias (svrs). 1bis interest has been
stimulated by the demonstration that accessory atrio-
ventricular (AV) connections in patients with Wolff-
Parkinson-White (WPW) syndrome can be selectively
damaged by radiofrequency energy (RP) delivered via
catheters insened percutaneously without general anaes-
thesia. The technique and results of its use were the
main topics of interest at the 9th World Symposium on
Cardiac Pacing and Electrophysiology held in
Washington, DC, in June 1991. Effective cure of WPW
syndrome entailing freedom from tachycardias without
drug treatment has been reponed in more than 90% of
patients undergoing this procedure. I Not surprisingly,
this has generated a great deal of excitement as previ-
ously these patients required either lifelong treatment
with potentially toxic anti-arrhythmic drugs or open-
hean surgery to ablate the accessory AV pathways
responsible for the tachycardias.2 The SVTs which are
amenable to treatment with RF current include atrial
fibrillation and flutter with uncontrollable ventricular
response (AV node ablation), ths: WPW syndrome
(accessory pathway ablation) and the extremely com-
mon form of SVT, AV nodal re-entrant tachycardia (AV
node modification).
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Practical techniques for the control of SVTs by
means of catheter ablation were first described in
1982Y High-energy DC shocks from a defibrillator
were transmitted via an electrode adjacent to the His
bundle. The aim was to induce complete hean block
to allow control of the ventricular rate in patients with
atrial flutter or fibrillation, otherwise uncontrollable by
drugs. Successful induction of complete hean block
required the implantation of a permanent pacemaker.
General anaesthesia was required because of the pain
and muscle spasm induced by the DC shock. The high
energies (200 - 300 J) resulted in arcing at the catheter
tip and vaporisation of blood that produced transient
pressures up to 20 atmospheres.' The resulting baro-
trauma may have been responsible for ventricular dys-
function and the production of arrhythmogenic foci.
Late sudden death has occurred in a small number of
patients.6 In addition, AV conduction recurred hours to
months later in a sizeable number of patients, presum-
ably because the AV node or proximal bundle of His
had been stunned rather than destroyed.
Alternative energy sources were therefore developed.
Modification of the output of the defibrillator allowed
the use of much lower energies (20 - 50 J), avoiding the
barotrauma while preserving the high-voltage heating
effect of the shock.' 1bis method is still in use, whereas
high-energy DC shock has largely been abandoned. In
1987, the use of RP energy from standard surgical
cautery machines was reponed. 8,- It was shown that
small, discrete lesions could be produced, providing the
catheter was in contact with the endocardium and suc-
cessful ablation of the AV node could be achieved. 'o
Because RF energy does not affect nerves or muscles,
general anaesthesia is not necessary. The homogeneous
lesions produced seem less likely to result in new
arrhythmias. The safety of the technique was somewhat
offset by a lower efficacy, probably because of the build-
-
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up of resistance due to charring of blood at the electrode
tip and because the smaller lesions required more pre-
cise positioning of the electrode. These problems have
been addressed by the development of specially
designed electrodes, which can be steered and have a
larger surface area. These have improved the success
rates." Rerum of conduction and late arrhythmias and
depression of cardiac mechanical performance have
been virtually eliminated.
High-energy DC shocks were tried in patients with
WPW syndrome, initially with limited success and signi-
ficant complications, particularly in those with left-sided
accessory pathways. However, more recently Warin er
al. 12 reported impressive results in a large series of
patients. They ablated left-sided pathways by placing
the catheter in the left atrium or the left ventricle adja-
cent to the mitral annulus. Nevertheless, it was the
advent of RF ablation that led to the current widespread
use of catheter ablation to treat patients with WPW syn-
drome. Pathways in all locations around the AV ring can
now be dealt with successfully. Left-sided pathways are
approached by passing the catheter across the aortic
valve into the left ventricle and curving it behind the
posterior leaflet of the mitral valve; the tip is placed
against the mitral annulus. Accurate location of the
accessory pathway by electrophysiological mapping of
the AV ring is essential and requires a fully equipped
electrophysiology laboratory and an experienced electro-
physiologist. Procedure times of 4 - 6 hours are usual
and may be considerably longer, but a high success rate
can be anticipated. A successful result means that the
patient is effectively cured without the need for surgery
or anti-arrhythmic drugs. This is both cost-effective and
gratifying in a condition which results in significant -
morbidity and occasionally causes sudden death. 13
Complication rates appear to be low 1 and recurrences
uncommon.
Where does this leave surgical treatment of WPW
syndrome? Despite the high success rates reported, ·it is
acknowledged that not all patients can be successfully
treated by catheter ablation. The treatment of those
with multiple accessory pathways and associated defects
such as Ebstein's anomaly of the tricuspid valve is more
likely to fail. So far, RF catheter ablation of accessory
pathways has been attempted in 14 patients with WPW
syndrome in South Africa and was successful in 8; 2
were successfully operated on after catheter ablation
failed, 1 of whom had Ebstein's anomaly with two
accessory pathways. There is undoubtedly a learning
curve with reported initial success rates around 50%"
and improved results are anticipated with greater experi-
ence. This, together with a relatively low complication
rate, augurs well for the future.
The other common cause of paroxysmal SVT is re-
entry within the AV node. While this usually responds
well to agents which delay AV nodal conduction ([3-
blockers, veraparnil, digitalis), it occasionally becomes a
major clinical problem and fails to respond even to the
more toxic anti-arrhythmic agents such as disopyramide,
propafenone or amiodarone. It is now possible to
modify the upper pan of the AV node by RF energy via
a catheter so that the retrograde pathway is selectively
damaged." Thi prevents further episodes of tachycardia
while leaving AV conduction intact. However, there is a
risk of about 10% that antegrade transmission will also
be damaged, resulting in AV block and the need for a
permanent pacemaker. It is to be hoped that refine-
ments in technique will reduce this risk so that the pro-
cedure can be offered to more patients.
\Xlhile these 'high-tech' solutions may seem inappro-
priate in the economic and social climate of present-day
South Africa, it should be remembered that the people
affected by these conditions are usually young and eco-
nomically active. A procedure which offers freedom
from daily medication and the fear of breakthrough
tachycardias has much to recommend it.
We would like to thank Drs T. Mabin, E. Uoyd and J.
Tyrrell for information about their patients.
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